This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
JAG1 · Western blot design guide
JAG1 Western Blot Planning Guide
Plan a JAG1 Western blot around the catalog-observed 133.8 kDa band, image-backed A00640-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
JAG1 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 133.8 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Skin | |
| Negative control | Bone marrow |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 133.8 kDa |
| ⓘ | Localization | Membrane / Cell membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated JAG1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Gallbladder |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A00640-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected JAG1 Western Blot Band Size?
Use the product-observed 133.8 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 133.8 kDa | Matches the authoritative product WB observation. |
| 133.8 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected JAG1 appearancePlan around 133.8 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 133.8 kDa; use this as the primary experimental expectation. |
| Calculated mass | 133.8 kDa from UniProt P78504; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A00640-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 133.8 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing JAG1 band
A00640-2 · JAG1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for JAG1 Western blot
🧪Use Skin as the first positive-control candidate and Bone marrow as the HPA Not detected negative candidate.
Positive control: Skin (High)
Negative control: Bone marrow (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for JAG1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Skin | Reported tissue cells | High | Protein (HPA) | HPA → |
| Gallbladder | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced JAG1 Western Blot Tips
Deeper troubleshooting and optimisation questions for JAG1, answered from its protein features.
Which band should guide the blot?
Use 133.8 kDa, the observation attached to the authoritative A00640-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 133.8 kDa expectation.
Which positive control should I start with?
Start with Skin, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bone marrow as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for JAG1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A00640-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
JAG1 Western Blot Reagents
Human-reactive JAG1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-Jagged1/JAG1 Antibody Picoband®
Cat # A00640-2
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P78504
- Human Protein Atlas — JAG1
- A00640-2 product record
- PMC9768120 — JAG1 is associated with the prognosis and metastasis in breast cancer (Scientific reports, 2022)
- PMC7418053 — The putative endogenous AHR ligand ITE reduces JAG1 and associated NOTCH1 signaling in triple negative breast cancer cells (Biochemical pharmacology, 2020)
- PMC12446204 — Antisense oligonucleotide-mediated upregulation of Jag1 ameliorates liver disease phenotypes in a mouse model of Alagille syndrome (Molecular therapy. Nucleic acids, 2025)